10月6日，Vaxcyte盘后下跌5.39%，报69.69美元。
消息面上，公司在肺炎疫苗三期试验成功刺激股价大涨逾50%后，宣布启动普通股、预先融资认股权证及可转换优先票据的公开发行计划。此举引发市场对股权稀释的担忧，形成短期获利回吐压力。
该公司是一家下一代疫苗创新企业，通过无细胞蛋白质合成平台开发预防致命传染病的疫苗，其31价肺炎球菌疫苗VAX-31预计2028年上半年提交FDA生物制品许可申请。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.